Klow - GHK-Cu (50 mg) / BPC-157 (10 mg) / TB-500 (10 mg) / and KPV (10 mg)

KLOW is a research peptide blend combining four peptides—GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg), and KPV (10 mg)—in an 80 mg formulation designed for synergistic effects in preclinical studies. Unlike Semaglutide, Tirzepatide, and Retatrutide, which are incretin-based therapies targeting GLP-1, GIP, and/or glucagon receptors for diabetes and weight management, KLOW focuses on tissue repair, inflammation control, and cellular regeneration.

• GHK-Cu: A copper-binding tripeptide that modulates gene expression, promoting wound healing, collagen synthesis, and skin regeneration while reducing oxidative stress.
• BPC-157: A pentadecapeptide derived from gastric proteins, studied for accelerating tissue repair, particularly in muscles, tendons, ligaments, and the gut, with neuroprotective and anti-inflammatory properties.
• TB-500: A synthetic fragment of thymosin beta-4, researched for enhancing cell migration, muscle repair, and angiogenesis, with potential antimicrobial and cardiovascular benefits.
• KPV: A tripeptide derived from alpha-MSH, investigated for its potent anti-inflammatory and immune-modulating effects, particularly in gut and skin health.

KLOW builds on the GLOW protocol (GHK-Cu, BPC-157, TB-500) by adding KPV for enhanced anti-inflammatory effects, targeting multiple pathways for tissue regeneration and immune balance. It is used exclusively in controlled laboratory settings, such as in vitro and in vivo preclinical models, to study wound healing, epithelial barrier integrity, and systemic inflammation. No clinical trials have yet examined this specific four-peptide combination, making its research investigational and focused on theoretical synergies.